Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Johnson and Johnson
AstraZeneca
Baxter
Express Scripts

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lansoprazole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00149084 ↗ Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Yokoyama Foundation for Clinical Pharmacology Phase 3 2003-04-01 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084 ↗ Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori Unknown status Hamamatsu University Phase 3 2003-04-01 The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00174928 ↗ A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease Completed Takeda Phase 1 2005-05-01 The purpose of this study is to understand how quickly lansoprazole, once daily (QD), improves feeding in premature babies or babies less than 28 days of age.
NCT00175032 ↗ A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin Completed Takeda Phase 3 2003-07-01 The purpose of this study is to compare the gastroduodenal ulceration rate, gastrointestinal complication rate and non-steroidal anti-inflammatory drug-associated dyspepsia between lansoprazole, naproxen and celecoxib, taken once daily (QD) or twice daily (BID), in participants with osteoarthritis taking low dose aspirin.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lansoprazole

Condition Name

Condition Name for Lansoprazole
Intervention Trials
Healthy 14
Erosive Esophagitis 12
Helicobacter Pylori Infection 11
Gastroesophageal Reflux 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lansoprazole
Intervention Trials
Gastroesophageal Reflux 37
Ulcer 23
Esophagitis 23
Helicobacter Infections 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lansoprazole

Trials by Country

Trials by Country for Lansoprazole
Location Trials
United States 358
Japan 341
China 107
Korea, Republic of 34
Taiwan 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lansoprazole
Location Trials
California 17
Texas 17
Florida 17
Missouri 16
Ohio 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lansoprazole

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole
Clinical Trial Phase Trials
Phase 4 61
Phase 3 50
Phase 2/Phase 3 2
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lansoprazole
Clinical Trial Phase Trials
Completed 117
Unknown status 18
Terminated 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lansoprazole

Sponsor Name

Sponsor Name for Lansoprazole
Sponsor Trials
Takeda 37
AstraZeneca 10
HK inno.N Corporation 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lansoprazole
Sponsor Trials
Other 141
Industry 105
NIH 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Baxter
Boehringer Ingelheim
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.